Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Sep
09
Today In Oncology
NSCLC FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease
Refined Risk Index Improves Outcome Prediction After Limited-Duration CLL Therapy
SUO/AUA Updates Guidelines for Non-Muscle Invasive Bladder Cancer
Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL
Early ctDNA Molecular Response May Predict Outcomes With Azenosertib in Ovarian Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo